Meloxicam

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Retrieved on: 
Tuesday, March 12, 2024
Webcast, Bupivacaine, Granisetron, Aprepitant, Meloxicam, Heron

ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.

Key Points: 
  • ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.
  • APONVIE® Net Product Sales: Net Product Sales of APONVIE for the three and twelve months ended December 31, 2023 were $0.5 million and $1.4 million, respectively, with no sales in the comparable prior year periods.
  • CINVANTI® Net Product Sales: Net Product Sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2023 were $24.3 million and $94.9 million, respectively, which increased from $23.1 million and $87.3 million, respectively, for the same periods in 2022.
  • SUSTOL® Net Product Sales: Net Product Sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2023 were $3.8 million and $13.0 million, respectively, which increased from $3.0 million and $10.2 million, respectively, for the same periods in 2022.

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Retrieved on: 
Wednesday, January 24, 2024
System, Death, Allergy, Heron, Patient, Vitamin, Naproxen, Elective surgery, SAN, Health, Partnership, Foot, Gastrointestinal bleeding, Ibuprofen, Vomiting, Anemia, Ankle, Stroke, Heart failure, Medicine, Nonsteroidal anti-inflammatory drug, Patient satisfaction, Cartilage, Risk, Meloxicam, Pain, VAN, Cross-link, Food, Constipation, Pregnancy, NDA, Anesthetic, Aspirin, Tears, FDA, Ulcer, Liver, Boxed warning, New Drug Application, Headache, Bupivacaine, Human, Blood, Pharmaceutical industry

SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.

Key Points: 
  • ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
  • This expanded indication for ZYNRELEF will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.
  • To obtain this labeling expansion, Heron successfully conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
  • The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.

Summary of opinion: Metacam, 17/01/2024 Positive

Retrieved on: 
Friday, January 19, 2024
European Medicines Agency, NSAID, Meloxicam, Civil service commission, European Commission, Dog, Intention, CVMP, UPD, Cat, SPC, Marketing, Committee

On 16 – 17 January 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Metacam.

Key Points: 
  • On 16 – 17 January 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Metacam.
  • The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.
  • Metacam is currently authorised for various therapeutic indications in different target species and is available as several pharmaceutical forms and strengths.
  • The active substance is meloxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class.

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-17 January 2024

Retrieved on: 
Friday, January 19, 2024
Classification, EMEA, Commission, Certification, Animal, Eukaryote, DNA, QWP, Decision-making, Meloxicam, AWP, Sheep, Dog, CEP, CVMP, IWP, Environment, Horse, Cat, The Committee, Cattle, MRL, Marketing, Committee, Guideline, Excipient, MAA, Medical device

CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Key Points: 


CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Summary of opinion: Metacam, 17/01/2024 Positive

Retrieved on: 
Friday, January 19, 2024
European Medicines Agency, NSAID, Meloxicam, Civil service commission, European Commission, Dog, Intention, CVMP, UPD, Cat, SPC, Marketing, Committee

On 16 – 17 January 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Metacam.

Key Points: 
  • On 16 – 17 January 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Metacam.
  • The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.
  • Metacam is currently authorised for various therapeutic indications in different target species and is available as several pharmaceutical forms and strengths.
  • The active substance is meloxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class.

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Retrieved on: 
Sunday, January 7, 2024
Partnership, Heron, Meloxicam, SAN, Therapy, Spine, Growth, Bupivacaine, Patient, Cross-link, VAN, Nursing

The partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout.

Key Points: 
  • The partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout.
  • In total, approximately 650 representatives will be added to Heron's sales network over the next year.
  • CrossLink will be the lead partner in the United States to expand ZYNRELEF promotion for orthopedic indications.
  • "CrossLink has a proven track record of success in building relationships, providing superior service to healthcare providers and improving patient outcomes.

United States ANJESO (meloxicam) Drug Insight and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Pharmaceutical, Meloxicam, Osteoarthritis, Pain, Rheumatoid arthritis, Clinical trial, Boehringer Ingelheim, Research, MOBIC, COX, SWOT, Poultry farming, Dietary supplement, Pharmaceutical industry

The "United States ANJESO Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States ANJESO Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about ANJESO for acute pain in the United States.
  • A detailed picture of the ANJESO for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the ANJESO for acute pain.
  • This report provides a detailed market assessment of ANJESO for acute pain in the United States.

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Retrieved on: 
Tuesday, November 14, 2023
Sale, Fresenius (company), EBITDA, Webcast, New product development, SAN, Markman, Therapy, Bupivacaine, Investment, Depreciation, Patient, VAN, Meloxicam, New Drug Application, Aprepitant, Growth, PDUFA, Heron, Patent, Optimism, Pharmaceutical industry, Risk management, Beauty salon, Cryptocurrency

I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.

Key Points: 
  • I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.
  • Guidance for 2023 and 2024:
    The Company is updating guidance for the remainder of 2023 and establishing guidance for the full year 2024 that reflects the growth potential of the product portfolio and the output of our continual operational improvements.
  • Full-year 2023 net product sales guidance for the oncology care franchise is being increased to a range of $104 million to $106 million from a prior range of $99 million to $103 million.
  • EBITDA (excluding stock compensation) expected in the range of ($10 million) to ($6 million) in the fourth quarter of 2023.

Melodea's Sustainable Barrier Coating Boosts Food Packaging Recyclability

Retrieved on: 
Wednesday, July 12, 2023
EVOH, Pressure, Plastic, Snack, Food preservation, CPG, COVID-19, The National German Sustainability Award, Recycling, Federal Institute for Risk Assessment, Meloxicam, Food packaging, Sustainability, FDA, EU

REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- Melodea, Ltd., a leading sustainable barrier coatings producer for packaging, introduces its newest innovation, MelOx NGen™. MelOx NGen is a high-performance barrier product specifically engineered to allow for the recyclability of plastic food packaging and beyond. In addition to its excellent eco-profile, the new barrier has proven superior in its key role of maintaining food freshness and substantially reducing plastic waste.

Key Points: 
  • REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- Melodea, Ltd., a leading sustainable barrier coatings producer for packaging, introduces its newest innovation, MelOx NGen™.
  • MelOx NGen is a high-performance barrier product specifically engineered to allow for the recyclability of plastic food packaging and beyond.
  • MelOx NGen, could help expand the scope of plastic food packaging eligible for recycling.
  • "EVOH, which is typically infused into the thin plastic films of the food packaging to serve as an oxygen barrier, is non-recyclable preventing the entire package from being recyclable.

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
Prescription Drug User Fee Act, Centers for Medicare & Medicaid Services, Marketing, New Drug Application, Meloxicam, Center for Medicare and Medicaid Innovation, Vomiting, Medicare, Net, Aprepitant, Shanda, Comparables, Bupivacaine, Patient, PONV, Investment, SAN, Heron, PDUFA, Webcast, Growth, Research, Therapy, Video game, Management, Pharmaceutical industry, Internet service provider, Cryptocurrency

SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.

Key Points: 
  • SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.
  • First quarter 2023 net product sales grew 26% to $29.6 million, compared to the first quarter of 2022.
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three months ended March 31, 2023 was $3.5 million.
  • Net product sales of APONVIE for the three months ended March 31, 2023 were $0.3 million.